Beyondspring (NASDAQ:BYSI) posted its quarterly earnings results on Wednesday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.31, Bloomberg Earnings reports.
Shares of BYSI stock opened at $19.80 on Friday. The company has a market cap of $450.29 million, a price-to-earnings ratio of -8.18 and a beta of 1.40. Beyondspring has a fifty-two week low of $13.06 and a fifty-two week high of $27.53. The stock has a 50 day simple moving average of $19.09.
BYSI has been the topic of several recent research reports. Maxim Group restated a “buy” rating and set a $58.00 price target on shares of Brinker International in a research report on Tuesday, April 30th. Zacks Investment Research upgraded General Moly from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Beyondspring in a research report on Wednesday.
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Featured Story: Golden Cross
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.